Pain management device combines heat therapy, electrical nerve stimulation

The topic of pain management is moving away from its current dependence on drugs into methods that incorporate therapy outside of medication. Omron Healthcare has introduced its Omron HEAT Pain Pro, which utilizes heat and transcutaneous electrical nerve stimulation (TENS) technology to treat joint and muscle pain.

Combining TENS, the sending of stimulating pulses across the skin to prevent pain signals from reaching the brain, and heat gives the Pain Pro an advanced over conventional treatments that only utilize one of the therapies and is recommended by physical therapists to give the most effective treatments for muscle and joint pain.

"Millions of Americans suffer from daily pain. Whether they are experiencing back pain, aching knees, joint pain or chronic discomfort, people are looking for more safe, effective pain management options," said Carol Lucarelli, director of marketing and product development for Omron Healthcare. "Increased awareness of the potential dangers of opioids and prescription pain killers is driving more consumer interest in pain management options. The Omron HEAT Pain Pro is a safe, effective, accessible drug-free choice."

The Omron HEAT Pain Pro uses 27 heat and 20 TENS combinations, with pre-set options for different areas of the body. The device is handheld and can be easily used in the home. The device features a rechargeable battery, gel pads that can be used up to 30 times and is available without a prescription.

 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.